Drug Trial Radar · NCT07184827
Evaluate the Efficacy and Safety of U101 Oral Capsules in the Prevention of Uncomplicated rUTIs in Women
Last checked: Nov 19, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
348
Planned (sponsor's estimate)
Start
Oct 14, 2020
Primary completion
Jun 30, 2028
Study completion Jul 31, 2028
Sponsor
- Lead sponsor
- TCM Biotech International Corp.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if drug U101 works to prevent recurrent urinary tract infection (rUTI) in women (≥ 20 and \< 76 years old) with a medical history. It will also investigate the safety and the impact on the Quality of Life improvement of drug U101. The main questions it aims to answer are: * Does the drug prevent or decrease the recurrence of urinary tract infection (UTI) during the 24-week treatment? * Will the Quality of Life be improved during the 24-week treatment? * What medical problems do participants have when taking drug U101? Researchers will compare drug U101 to a placebo (a look-alike substance that contains no drug) to see if drug U101 works to prevent rUTI. Participants will: * Orally take drug U101 or placebo every day for 24 weeks in the main study, three times per day (TID) for 8 weeks and twice per day (BID) for 16 weeks. * Visit the site once every 4 weeks for checkups and tests during the main study. * be asked to enroll in extensional study (the open-label extension (OLE) with drug U101 treatment or the Safety Follow-Up Visits with no investigational product treatment) for 24 weeks after they complete the 24-week main study. * Visit the site when the suspected UTI occurred during the main study or the extension study.
Conditions
- Recurrent Urinary Tract Infections in Women
Interventions
U101Drug
One capsule (100 mg) of U101 will be administered orally three times per day (TID) for 8 weeks followed by one capsule of U101 twice per day (BID) for 16 weeks.
PlaceboOther
One capsule of Placebo will be administered orally three times per day (TID) for 8 weeks followed by one capsule of placebo twice per day (BID) for 16 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects without UTI recurrence during the 24-week main study periodTime frame: The primary analysis will be performed at the end of the 24-week main study
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Chang Gung Memorial Hospital, Chiayi Branch
Chiayi City, Taiwan · Recruiting
Taiwan Provincial Yun-Lin Hospital
Douliu, Taiwan · Recruiting
Chang Gung Memorial Hospital, Kaohsiung Branch
Kaohsiung City, Taiwan · Recruiting
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, Taiwan · Active not recruiting
Kaohsiung Veterans General Hospital
Kaohsiung City, Taiwan · Recruiting
Taipei Tzu Chi Hospital
New Taipei City, Taiwan · Recruiting
China Medical University Hospital
Taichung, Taiwan · Recruiting
Chung Shan Medical University Hospital
Taichung, Taiwan · Recruiting
Taichung Veterans General Hospital
Taichung, Taiwan · Recruiting
National Cheng Kung University Hospital
Tainan, Taiwan · Recruiting
Chang Gung Memorial Hospital, Taipei Branch
Taipei, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taiwan · Recruiting
Taipei City Hospital, Renai Branch
Taipei, Taiwan · Recruiting
Taipei City Hospital, Yangming Branch
Taipei, Taiwan · Recruiting
Taipei Medical University Hospital
Taipei, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taiwan · Recruiting
Tri-Service General Hospital (TSGH)
Taipei, Taiwan · Recruiting
Chang Gung Memorial Hospital, Linkuo Branch
Taoyuan, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.